scholarly journals Prediction of tumour grade and survival outcome using pre-treatment PET- and MRI-derived imaging features in patients with resectable pancreatic ductal adenocarcinoma

2020 ◽  
Author(s):  
Vincent Dunet ◽  
Nermin Halkic ◽  
Christine Sempoux ◽  
Nicolas Demartines ◽  
Michael Montemurro ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Survival Outcome ◽  
Ductal Adenocarcinoma ◽  
Imaging Features ◽  
Tumour Grade ◽  
Pre Treatment

Characterization of undiagnosed pancreatic ductal adenocarcinoma on CT scans.

2021 ◽  
Vol 39 (3_suppl) ◽  
pp. 380-380
Author(s):  
John Chang ◽  
Madelyn Bartels ◽  
Kelsey Beyer ◽  
Ashley Maitland ◽  
Richard Taft Peterson ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
The Body ◽  
Ct Scans ◽  
Ductal Adenocarcinoma ◽  
Imaging Features ◽  
Cognitive Errors ◽  
Radiologic Findings ◽  
Stage 1 ◽  
Improved Technology ◽  
Radiologic Features

380 Background: Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related deaths. At present, the best 5-year survival is 25% for resectable PDAC. For small (1 cm) stage 1 PDAC, resection has resulted in much better survival. The goal of this study was to evaluate the appearance and location of early undiagnosed PDAC on computed tomography scans (CT) prior to diagnosis with the goal of minimizing missing early PDAC. We also categorize the errors as either perceptive or cognitive. Methods: PDAC cases were retrospectively reviewed from 1/1/2012 through 12/31/2018 from our tumor registry, identifying 81 cases with paired CT scans both at the time of and prior to diagnosis. Among these, 31 contained imaging features considered diagnostic or suspicious for early PDAC(38%). These “errors” were classified by radiologic features and as well as by location. In addition, errors were classified into “perceptive errors" when the first study was read as normal, and as “cognitive errors” when the report noted an abnormality but failed to note suspicion for malignancy. Results: Among the 31 undiagnosed PDAC, 18 had features of an identifiable mass (58%), 9 had pancreatic ductal dilatation (29%), and 4 had evidence of perivascular soft tissue (13%). 44% of undiagnosed tumors were located in the head-neck, 39% in the body, and 17% in the tail. Perceptive errors were found in 58% and 42% were cognitive. No significant differences were seen between perceptive and cognitive errors based on suspicious features. Conclusions: Radiologic findings of early PDAC was retrospectively evident in more than one third of cases in which prior imaging was performed. These findings are most often masses or ductal dilatation. Location of these undiagnosed tumors were distributed throughout the gland. This study identifies the radiologic features of undiagnosed PDAC which may provide an opportunity for future prospective studies and improved technology which may improve early detection of pancreatic cancer.

Diffuse pancreatic ductal adenocarcinoma: Characteristic imaging features

2008 ◽  
Vol 67 (2) ◽  
pp. 321-328 ◽  
Author(s):  
Young Jun Choi ◽  
Jae Ho Byun ◽  
Ji-Youn Kim ◽  
Myung-Hwan Kim ◽  
Se Jin Jang ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Ductal Adenocarcinoma ◽  
Imaging Features ◽  
Characteristic Imaging

scholarly journals High mRNA expression of LY6 gene family is associated with overall survival outcome in pancreatic ductal adenocarcinoma

Oncotarget ◽  
2021 ◽  
Vol 12 (3) ◽  
pp. 145-159
Author(s):  
Eric Russ ◽  
Krithika Bhuvaneshwar ◽  
Guisong Wang ◽  
Benjamin Jin ◽  
Michele M. Gage ◽  
...  
Keyword(s):  
Overall Survival ◽  
Gene Family ◽  
Mrna Expression ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Survival Outcome ◽  
Ductal Adenocarcinoma

scholarly journals Imaging features of pancreatic metastases: A comparison with pancreatic ductal adenocarcinoma

2018 ◽  
Vol 51 ◽  
pp. 76-82 ◽  
Author(s):  
Massimo Galia ◽  
Domenico Albano ◽  
Dario Picone ◽  
Maria Chiara Terranova ◽  
Antonino Agrusa ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Ductal Adenocarcinoma ◽  
Imaging Features ◽  
Pancreatic Metastases

Prognostic significance of nutritional and inflammatory markers in patients with unresectable pancreatic ductal adenocarcinoma treated with chemotherapy.

2019 ◽  
Vol 37 (4_suppl) ◽  
pp. 219-219
Author(s):  
Ryosuke Kobiyama ◽  
Isaku Yoshioka ◽  
Takayuki Ando ◽  
Shinya Kajiura ◽  
Kazuto Shibuya ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Inflammatory Markers ◽  
Ductal Adenocarcinoma ◽  
Serum Cholinesterase ◽  
First Line ◽  
Lymphocyte Ratio ◽  
First Line Therapy ◽  
Line Therapy ◽  
Pre Treatment ◽  
Conut Score

219 Background: Recently, several nutritional and inflammatory markers have been reported to be involved in cancer progression. The aim of this study is to evaluate whether nutritional and inflammatory biomarkers such as the modified Glasgow prognostic score (mGPS), the neutrophil‐to-lymphocyte ratio (NLR), the platelet‐to-lymphocyte ratio, the systemic-immune-inflammation index (SIII), controlling nutritional status (CONUT) score, prognostic nutritional index, and the lymphocyte‐to-monocyte ratio (LMR) could predict the prognosis in patients with unresectable pancreatic ductal adenocarcinoma (UR-PDAC) who underwent chemotherapy as first-line therapy, using disease-specific survival as the primary outcome. Methods: All UR-PDAC patients were retrospectively evaluated between January 2011 and May 2017 at Toyama University Hospital. Baseline clinicopathological characteristics and pre-treatment laboratory values such as absolute neutrophil, lymphocyte and platelet counts, C-reactive protein, albumin and CA19-9 levels, were collected. Results: A total of 184 patients were diagnosed as UR-PDAC. Among them, 151 patients who underwent chemotherapy were enrolled in this study. There were significant relationships between survival and elevated mGPS, elevated NLR, elevated SIII, decreased LMR, decreased serum cholinesterase level, and low CONUT score (p < 0.001, p < 0.001, p = 0.001, p < 0.001, p = 0.026 and p < 0.001, respectively, by log-rank test). The median survival time of patients with metastatic lesions was significantly shorter than that of patients with unresectable locally advanced PDAC (9.0 vs 15.5 months, respectively; p = 0.033). There was no significant difference in survival in pre-treatment CA19-9 level and tumor location. Multivariate analysis using Cox regression model revealed that NLR and CONUT score were independent prognostic factors. Conclusions: Pre-treatment NLR and CONUT score may predict clinical outcome in patients with UR-PDAC undergoing chemotherapy as first-line therapy.

scholarly journals High-Percentage of Early Resectable Pancreatic Ductal Adenocarcinoma is Unidentified on Abdominal CT Obtained for Unrelated Diagnosis

2021 ◽  
Author(s):  
Talayna Leonard ◽  
◽  
Robert Lemme ◽  
Cati Kral ◽  
Briana Santiago ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Clinical Diagnosis ◽  
Cross Sectional Study ◽  
Ductal Adenocarcinoma ◽  
Imaging Features ◽  
Cross Sectional ◽  
Tumor Registry ◽  
One Year ◽  
Improve Patient

Objective: Pancreatic ductal adenocarcinoma (PDAC) has the best survival when detected early with 5-year survival near 40% for small, resectable PDAC. We evaluate the undiagnosed PDAC imaging features on routine CT and their impact on resectability. Methods: 76 of the screened 134 CTs from 1/1/2012 to 12/31/2018 using our tumor registry were obtained prior to PDAC diagnosis for other indications at least one month before presentation. Each cross-sectional study was reviewed for features of early PDAC: pancreatic mass, pancreatic ductal dilatation, perivascular/peripancreatic soft-tissue infiltration, omental lesions/ascites, and lymphadenopathy. When such features were detectible by the reviewing radiologists, the original CT readings were classified as concordant/discrepant. Descriptive statistics are reported for discrepant reads, tumor resectability, and tumor size. Results: Of the 76 cases from 46 unique subjects (30 male/16 female), 25 CTs (33%) had undetected PDAC imaging features: masses (15/19 unreported), ductal dilatation (16/20 unreported), and peripancreatic/perivascular soft-tissue infiltration (20/36 unreported). 63% of early PDAC features were not identified initially. One year before clinical diagnosis, 75-80% of the PDAC cases were resectable; at < 6 months before clinical diagnosis, only 29% were resectable. Conclusion: Improving early detection of key PDAC features on routine CT examinations can potentially improve patient outcomes.

Validation of Prognostic Radiomic Features From Resectable Pancreatic Ductal Adenocarcinoma in Patients With Advanced Disease Undergoing Chemotherapy

2020 ◽  
pp. 084653712096878
Author(s):  
Emmanuel Salinas-Miranda ◽  
Farzad Khalvati ◽  
Kashayar Namdar ◽  
Dominik Deniffel ◽  
Xin Dong ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Advanced Disease ◽  
Ductal Adenocarcinoma ◽  
P Value ◽  
Significant Prognostic Factor ◽  
Test Set ◽  
Cox Proportional Hazard ◽  
Stage Disease ◽  
Cox Proportional Hazard Models ◽  
Pre Treatment

Background: Radiomic features in pancreatic ductal adenocarcinoma (PDAC) often lack validation in independent test sets or are limited to early or late stage disease. Given the lethal nature of PDAC it is possible that there are similarities in radiomic features of both early and advanced disease reflective of aggressive biology. Purpose: To assess the performance of prognostic radiomic features previously published in patients with resectable PDAC in a test set of patients with unresectable PDAC undergoing chemotherapy. Methods: The pre-treatment CT of 108 patients enrolled in a prospective chemotherapy trial were used as a test cohort for 2 previously published prognostic radiomic features in resectable PDAC (Sum Entropy and Cluster Tendency with square-root filter[Sqrt]). We assessed the performance of these 2 radiomic features for the prediction of overall survival (OS) and time to progression (TTP) using Cox proportional-hazard models. Results: Sqrt Cluster Tendency was significantly associated with outcome with a hazard ratio (HR) of 1.27(for primary pancreatic tumor plus local nodes), (Confidence Interval(CI):1.01 -1.6, P-value = 0.039) for OS and a HR of 1.25(CI:1.00 -1.55, P-value = 0.047) for TTP. Sum entropy was not associated with outcomes. Sqrt Cluster Tendency remained significant in multivariate analysis. Conclusion: The CT radiomic feature Sqrt Cluster Tendency, previously demonstrated to be prognostic in resectable PDAC, remained a significant prognostic factor for OS and TTP in a test set of unresectable PDAC patients. This radiomic feature warrants further investigation to understand its biologic correlates and CT applicability in PDAC patients.

Sign in / Sign up

Export Citation Format

Share Document